Momentum builds around new antibiotic business models

The Innovative Medicines Initiative's DRIVE-AB project joins the fray of task forces working to reinvigorate interest in antibiotics by developing reimbursement models that delink revenue from sales volume.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: The number of systemic antibiotic approvals declined steadily from 1980 to 2009.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Momentum builds around new antibiotic business models. Nat Rev Drug Discov 13, 711–713 (2014).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing